Positions
- Professor
-
Pharmacology and Chemical Biology
Baylor College of Medicine
Houston, Texas United States
- Professor
-
Molecular and Cellular Biology
Baylor College of Medicine
Houston, Texas United States
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States
- Member
-
Center for Drug Discovery
Baylor College of Medicine
Houston, Texas United States
Addresses
- 1 Baylor Plaza (Office)
-
Room: Alkek N520.05
Houston, TX 77030
United States
Phone: (713) 798-6875
wangj@bcm.edu
Education
- BS from Peking University
- 07/2003 - Beijing, China
- Chemistry
- PhD from The Ohio State University
- 12/2007 - Columbus, Ohio United States
- Organic Chemistry
- Postdoctoral Training at University of North Carolina at Chapel Hill
- 05/2011 - Chapel Hill, North Carolina United States
- Drug Delivery and Nanomedicine
Professional Interests
- Chemical Biology, Sensing and Imaging, Drug Discovery, PROTACs, Antibody Drug Conjugates, Proteomics and Metabolomics
Professional Statement
The overarching goal for my research is to develop new tools to address biological questions and new therapies to improve human health, taking advantage of my unique experience in organic and medicinal chemistry, drug delivery, material sciences, cell biology and preclinical studies. My laboratory has developed the first reversible reaction-based fluorescent probe to monitor glutathione (GSH) dynamics in living cells and the first potent and safe small molecule inhibitor (SMI) for steroid receptor coactivator-3 (SRC-3) as a novel targeted cancer therapy. Furthermore, we recently discovered a novel strategy to enhance intracellular accumulation and target engagement for protein degraders (PROTACs). Additionally, we develop novel antibody-drug conjugates as anticancer therapeutics.Websites
VIICTR Research Database
Selected Publications
- Wen-Hao Guo, Xiaoli Qi, Yang Liu, Chan-I Chung, Fang Bai, Xingcheng Lin, Lingfei Wang, Jianwei Chen, Krystle J. Nomie, Feng Li, Meng C. Wang, Xiaokun Shu, José N. Onuchic, Jennifer A. Woyach, Michael L. Wang, Jin Wang* "Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry." Nature Communications. 2020 11 : 4268. Pubmed PMID: 32848159
- Jiang X, Chen J, Bajić A, Zhang C, Song X, Carroll SL, Cai ZL, Tang M, Xue M, Cheng N, Schaaf CP, Li F, MacKenzie KR, Ferreon ACM, Xia F, Wang MC, Maletić-Savatić M, Wang J "Quantitative real-time imaging of glutathione." Nature Communications. 2017 July 13; 8 : 16087. Pubmed PMID: 28703127
- Song X, Chen J, Zhao M, Zhang C, Yu Y, Lonard DM, Chow DC, Palzkill T, Xu J, O'Malley BW, Wang J. "Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3." Proc Natl Acad Sci USA. 2016 May 3; 113 (18): 4970-5. Pubmed PMID: 27084884
- "Quantitative Imaging of Glutathione in Live Cells Using a Reversible Reaction-Based Ratiometric Fluorescent Probe." ACS Chem Bio. 2015 January 6; 10 (3): 864–874. Pubmed PMID: 25531746
- "Precisely Tunable Engineering of Sub-30 nm Monodisperse Oligonucleotide Nanoparticles." J. Am. Chem. Soc.. 2014 136 (1): 234–240. Pubmed PMID: 24344996
- Jianwei Chen, Mingkun Zhao, Fude Feng, Antons Sizovs, and Jin Wang "Tunable Thioesters as “Reduction” Responsive Functionality for Traceless Reversible Protein PEGylation." J. Am. Chem. Soc.. 2013 July 12; 135 (30): 10938–10941.
Funding
- Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease - #U01AG068031 (09/15/2020 - 05/31/2025) Grant funding from NIH/NIA
- Reversible Covalent BTK Degraders As the Next Generation Targeted Therapy To Treat B-Cell Malignancies - #R01CA250503 (07/01/2020 - 06/30/2025) Grant funding from NIH/NCI
- TARGETING A LIPID-MEDIATED PRO-LONGEVITY PATHWAY AS ALZHEIMER'S THERAPY - #RF1AG062257 (09/15/2018 - 06/30/2023) Grant funding from NIH/NIA
- Drugging the Undruggable Coactivators using Small Molecule Inhibitors - #R01CA207701 (03/15/2017 - 02/28/2022) Grant funding from NIH/NCI
- Real-Time Quantitative Imaging of Intracellular Biothiol Dynamics - #R01GM115622 (09/22/2015 - 07/31/2021) Grant funding from NIH/NIGMS
- Engineering Antibody Drug Conjugates to Target P53-Defective Triple Negative Breast Cancer - #R21CA213535 (06/13/2017 - 05/31/2019) Grant funding from NIH/NCI
Intellectual Property
- Product Patent (Pending)
- Co Inventors: Xiqian Jiang; Jianwei Chen
- Product Patent (Approved)
- Co Inventors: Fude Feng
- Product Patent (Approved)
- Co Inventors: Bert W. O’Malley, David M. Lonard, Jianming Xu, and Jianwei Chen
- Product Patent (Pending)
- Co Inventors: Jin Wang, Wen-Hao Guo, Xiaoli Qi, Michael Wang, Krystle Nomie, and Yang Yu
- Product Patent (Pending)
- Co Inventors: Jin Wang, Hui Zheng, Lisheng Deng, and Anamitra Ghosh
Log In to edit your profile